April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
The effects of anti-vascular endothelial growth factor on cell viability, oxidative stress and mitochondrial bioenergetics
Author Affiliations & Notes
  • Shwu-Jiuan Sheu
    Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
    National Yang Ming Univerisity, Taipei, Taiwan
  • Ni-Chun Liu
    Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
  • Julie Y.H. Chan
    Center for Translational Research in Biomedical Science, Kaohsiung Chang Gung Memorial Hospital,, Kaohsiung, Taiwan
  • Footnotes
    Commercial Relationships Shwu-Jiuan Sheu, None; Ni-Chun Liu, None; Julie Y.H. Chan, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6326. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shwu-Jiuan Sheu, Ni-Chun Liu, Julie Y.H. Chan; The effects of anti-vascular endothelial growth factor on cell viability, oxidative stress and mitochondrial bioenergetics. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6326.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Age-related macular degeneration (AMD) is one of the major causes of adult visual loss. The vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular AMD. Anti-VEGF agents have been emerged as potential therapeutics for the treatment of AMD. The long-term effect of the anti-VEGF agent is desirable; however, possible short-term or long-term toxicity is not fully understood. The purpose of this study was to test the effects of two anti-VEGF agents on the cell viability and mitochondrial bioenergetics in human retinal pigment epithelial (RPE) cells.

Methods: Cell viability was tested in cultured APRE-19 cells treated with aflibercept (0.125, 0.5, or 2 mg) or ranibizumab (0.125, 0.25, or 0.5 mg) for 72 hours alone or pretreated the agents for 24 hours followed by acrolein (25 μM). Mitochondrial biogenesis was evaluated by Seahorse XF24 Extracellular Flux Analyzer at different time points after exposure to aflibercept or ranibizumab.

Results: After 72-h exposure, both aflibercep and ranibizumab caused mild reduction in cell viability; however, pretreatment with these two agents rescued the oxidative damage induced by acrolein on APRE-19 cells. Both aflibercep and ranibizumab increased basal and maximal mitochondrial respiratory capacity after short-term exposure (1 or 24 h), but returned to baseline following a long-time exposure (48 or 72 h).

Conclusions: Our results suggest that aflibercep and ranibizumab might exert protection against acrolein-induced oxidative cytotoxicity in human ARPE-19 cells via increases in the mitochondrial bioenergetics. Early alteration in mitochondrial reserve capacity might predict possible anti-oxidative effects of the agents.

Keywords: 701 retinal pigment epithelium • 600 mitochondria  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.